Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Participants needed: 180
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Adcendo ApSUpdated: Jul 2, 2026Locations: 7
Eligibility criteria

Histologically or cytologically confirmed diagnosis of solid tumor [+7]

Treatment with systemic anticancer therapy, including any investigational agent... [+10]

Read more
Status: Recruiting

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.

Participants needed: 210
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Adcendo ApSUpdated: Apr 17, 2026Locations: 11
Eligibility criteria

Patients must have pathologically confirmed unresectable advanced solid tumor [+7]

Prior treatment with any agent targeting Tissue Factor or any ADC with a topoiso... [+9]

Read more
Status: Recruiting

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

Participants needed: 270
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Adcendo ApSUpdated: Jan 28, 2026Locations: 8
Eligibility criteria

≥ 18 years of age [+7]

Patients who have had systemic anticancer therapy, including any investigational... [+5]

Read more